CCL2 and cancer: Importantly, IL-17 from Th17 cells and MCs in EC TME can promote cancer cell release of CXCL9/10, CXCL2/3, and CCL2/20, which can increase the infiltration and anti-tumor effects of NK cells, neutrophils, and CD1α+ DCs, respectively, and predict favorable prognosis for patients with esophageal tumors.